ACADIA Pharmaceuticals Inc at Guggenheim Securities Inflammation & Immunology Conference Transcript
All right. Welcome back, everyone, to the final session of Guggenheim's I&I Conference. My name is Eddie Hickman. I'm one of the biotech analysts here. And I'm joined today by some of the ACADIA management team, CFO, Mark Schneyer; and Doug Williamson, the Head of R&D. Welcome, gentlemen. Mark, do you maybe want to give -- spend 5 minutes giving us a quick overview of the company? And maybe you just recently reported earnings. So maybe just give us a summary of what you saw on some of the programs that are going ahead.
Yes, happy to do it. Thank you for having us. So at ACADIA, we're developing and commercializing novel medicines in CNS disorders. We're a commercial-stage organization as well as we have a pipeline behind it. The 2 commercial stage assets. So you alluded to DAYBUE, which is the first and only approved product to treat Rett syndrome, which is a neurodevelopmental disorder. It was approved
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
